BioNTech now plans to deliver 2 billion COVID-19 vaccines in 2021

BioNTech headquarters.
(Image credit: DANIEL ROLAND/AFP via Getty Images)

BioNTech, the German biotechnology firm that partnered with Pfizer to produce one of the two COVID-19 vaccines authorized for emergency use in the United States, is upping its 2021 vaccine delivery target to 2 billion doses, the company announced Monday.

Previously, the goal was to distribute 1.3 billion doses, but the use of a special syringe that allows six doses, rather than five, to be extracted from a standard vaccine vial was a driving force in raising the bar, Reuters reports. A new production site in Marburg, Germany, will become operational at the end of February and additional capacity by contractors supplying ingredients and filling the finished substance into vials will contribute to the new distribution goal. Read more at Reuters.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.